{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
  "id": "02975667",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
  "summary": "- **Revenue milestone**: FY revenue exceeded $200M for the first time ($208M total sales).  \n- **Core market strength**: Australasia delivered $181M in sales, supporting $300M FY27 revenue target.  \n- **North American expansion**:  \n  - Launched Maxigesic IV/tablet (Combogesic) in the US and Canada (combined addressable market >US$8B).  \n  - Restructured US distribution to optimize postoperative care sales.  \n- **Pipeline progress**:  \n  - 8 patented products in R&D, 24 off-patent injectables, and 5 advanced programs entering commercialization (e.g., Crystaderm, Micolette).  \n- **Financials**:  \n  - Net debt reduced to $14.5M (from $16.2M).  \n  - Dividend increased to 1.8 cents/share (from 1.6 cents).  \n- **Share price concerns**: Management believes the share price undervalues growth potential and pipeline.  \n- **Challenges**: FY25 saw temporary headwinds (client destocking, doctors\u2019 strike), but H2 recovery occurred.  \n\nNo material capital markets actions (e.g., raising, trading halts) identified.",
  "usage": {
    "prompt_tokens": 1984,
    "completion_tokens": 258,
    "total_tokens": 2242,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T22:17:22.156940"
}